General Information of Drug (ID: DMZTGN2)

Drug Name
Methylnaltrexone bromide Drug Info
Synonyms
Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, > W-5330; CHIR-01020
Indication
Disease Entry ICD 11 Status REF
Opioid-induced constipation DB32.1 Approved [1]
Obesity 5B81 Preclinical [2]
Cross-matching ID
PubChem CID
5361917
CAS Number
73232-52-7
TTD ID
D03YVO
ACDINA ID
D01244

Full List of Drug Formulations Containing This Drug

Methylnaltrexone Bromide 150mg tablet
Company Formulation ID FDA Description
Salix Pharms F23817 Silicified Microcrystalline Cellulose; Microcrystalline Cellulose; Sodium Lauryl Sulfate; Croscarmellose Sodium; Crospovidone; Poloxamer 407; Stearic Acid (Vegetable Source); Colloidal Silicon Dioxide; Edetate Calcium Disodium; Polyvinyl Alcohol; Titanium Dioxide; Polyethylene Glycol; Talc
------------------------------------------------------------------------------------
Methylnaltrexone Bromide 8mg/0.4ml solution
Company Formulation ID FDA Description
Salix Pharms F24216 Sodium Chloride; Edetate Calcium Disodium; Glycine Hydrochloride
------------------------------------------------------------------------------------
Methylnaltrexone Bromide 12mg/0.6ml solution
Company Formulation ID FDA Description
Salix Pharms F24217 Sodium Chloride; Edetate Calcium Disodium; Glycine Hydrochloride
------------------------------------------------------------------------------------

References

1 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
2 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.